- A pharmacy manager is developing a training program for employees who will handle hazardous drugs (HDs). To comply with USP <800>, what must be documented regarding personnel competency?
Answer: Direct observation of each employee demonstrating proper HD handling techniques.
USP <800> requires that competency be reassessed at least every 12 months, or when a new HD or new equipment is introduced. This assessment must include the demonstrated skill of the employee, which means competency must be documented through direct observation of their technique (e.g., hand hygiene, garbing, compounding). While exams and signed acknowledgments are useful, they do not replace the requirement for skill demonstration.
- To verify the effectiveness of cleaning procedures, USP <800> recommends routine environmental monitoring in the pharmacy. What does this monitoring typically involve?
Answer: Performing surface wipe sampling for specific HD residues at defined intervals.
Environmental monitoring for HD contamination involves performing surface wipe sampling to test for the presence of specific HD residues. This is done periodically (e.g., every 6 months) to verify that containment strategies and cleaning procedures are effective. Air sampling tests for microbial contamination, pressure monitoring is a daily check of engineering controls, and HEPA filter testing is part of certification, but none of these directly measure surface contamination with HDs.
- According to NIOSH and EPA regulations, how should a pharmacy dispose of empty stock vials that previously contained a P-listed antineoplastic agent like arsenic trioxide?
Answer: They must be segregated and disposed of as RCRA hazardous chemical waste in a black container.
Empty containers of P-listed hazardous wastes under RCRA, which includes several antineoplastic agents like arsenic trioxide, are considered acutely hazardous waste. They must be managed as bulk hazardous chemical waste, which typically involves segregation into a black RCRA-approved container. Trace chemotherapy (yellow) containers are for items contaminated with trace amounts of non-P-listed chemo. Rinsing does not reclassify the container.
- A pharmacist is reviewing the pharmacy's list of hazardous drugs (HDs). Which of the following drugs requires full USP <800> containment strategies for any manipulation and is NOT eligible for an Assessment of Risk (AoR) to permit alternative containment?
Answer: Methotrexate tablets
Methotrexate is a NIOSH Table 1 antineoplastic drug. Any manipulation of a Table 1 drug, including crushing a tablet for a non-sterile compound, requires full USP <800> containment strategies. Drugs on Table 1 are not eligible for an Assessment of Risk to create alternative, less stringent containment strategies. Warfarin, Finasteride, and Spironolactone are on NIOSH Tables 2 or 3 and may be eligible for an AoR if they are final dosage forms that do not require manipulation.
- A hospital pharmacy stores vials of carmustine for injection, an antineoplastic HD that requires refrigeration. Which of the following storage arrangements is compliant with USP <800> standards?
Answer: In a dedicated refrigerator located within a room under negative pressure with at least 12 air changes per hour (ACPH).
Antineoplastic HDs requiring refrigeration, like carmustine, must be stored in a dedicated refrigerator within a negative pressure area that provides at least 12 ACPH. Storing them with non-HD stock, in positive pressure rooms, or relying solely on a transport bag for containment in a general refrigerator is not compliant.
- A pharmacy needs to repackage methotrexate tablets from a bulk bottle into unit-dose blister packs. Which of the following conditions is required for this activity?
Answer: The activity must be performed within a Containment Primary Engineering Control (C-PEC).
Repackaging and manipulating HDs, even in solid dosage forms like tablets, generates particles and poses an exposure risk. USP <800> requires such activities to be performed in a C-PEC, such as a Containment Ventilated Enclosure (CVE), to protect personnel. Performing this in the open pharmacy or a positive pressure room is not permitted. The required PPE would also be more extensive than a single pair of non-chemo gloves and a mask.
- A hospital is implementing a medical surveillance program as recommended by NIOSH for its staff who handle hazardous drugs. What is a primary goal of this program?
Answer: To establish a baseline and detect the earliest reversible signs of health changes from exposure.
The primary purpose of a medical surveillance program is occupational safety. It aims to establish a worker's baseline health status before they begin working with HDs and then monitor for any early, subtle, or reversible health effects that could be linked to chemical exposure. This allows for intervention before a serious health issue develops. It is not for treatment, discipline, or solely for liability purposes.
- A pharmacist is explaining the NIOSH list of hazardous drugs to a new technician. What is the primary characteristic that distinguishes NIOSH Table 1 drugs from those on Tables 2 and 3?
Answer: Table 1 drugs are antineoplastic agents that require special handling.
The defining characteristic of NIOSH Table 1 is that it contains antineoplastic drugs. These are treated with the highest level of caution. While many have reproductive risks or are administered IV, the unifying feature is their classification as antineoplastic. Table 2 contains non-antineoplastic HDs, and Table 3 contains HDs that primarily pose a reproductive risk.
- A nurse is preparing to administer an intact, coated cyclophosphamide tablet to a patient on a medical floor. The hospital has not performed an Assessment of Risk for this drug. What is the minimum Personal Protective Equipment (PPE) required for this task according to USP <800>?
Answer: A single pair of ASTM D6978-rated chemotherapy gloves.
For administering intact tablets or capsules of antineoplastic HDs (Table 1), a single pair of chemotherapy gloves is the minimum required PPE. Gowns are only required if there is a risk of splashing or if the dosage form is injectable. Because no AoR was performed, the default handling precautions apply. Claiming no PPE is needed is incorrect because exposure can still occur.
- A pharmacist is preparing to compound a sterile IV solution of docetaxel, a NIOSH Table 1 hazardous drug. What is the minimum Personal Protective Equipment (PPE) required for this activity?
Answer: Two pairs of chemotherapy gloves, a disposable gown tested to resist permeability by HDs, head/hair covers, and shoe covers.
When compounding a sterile HD, USP <800> requires extensive PPE including two pairs of ASTM-rated chemotherapy gloves, a disposable gown impermeable to HDs, head and hair covers, and two pairs of shoe covers (one worn inside the C-SEC, one removed upon exit). Respiratory protection is not routinely required when working within a properly functioning C-PEC that provides adequate containment.
- While unpacking an order, a pharmacy stock clerk discovers that a bottle of liquid cyclophosphamide has broken inside a sealed plastic bag from the supplier. The exterior of the bag is not contaminated. What is the correct immediate action?
Answer: Isolate the damaged package, label it as hazardous, and contact the supplier for instructions.
When a damaged package containing an HD is received, it should not be opened. The package should be immediately isolated in a containment area (e.g., a negative pressure room) to prevent any potential exposure. The pharmacy should then contact the supplier for specific instructions on how to handle the return or disposal of the damaged item. Opening it creates a spill, and returning it without authorization is improper.
- When cleaning a surface contaminated with a hazardous drug, USP <800> requires a three-step process. Which agent is most appropriate for the decontamination step?
Answer: A 2% sodium hypochlorite solution or a peroxide-based agent
Decontamination is the first step and requires an agent that can chemically deactivate or neutralize the hazardous drug. Sodium hypochlorite (bleach) and peroxide-based formulations are common decontaminating agents. IPA is a disinfectant used in the final step. Germicidal detergents are used for the second step, cleaning. Sterile water is not an effective decontaminating agent.
- After completing a session of compounding with cyclophosphamide, a technician must clean the interior surfaces of the Containment Primary Engineering Control (C-PEC). What is the correct sequence of steps?
Answer: Decontaminate, then clean, then disinfect.
USP <800> requires a three-step process for cleaning areas and equipment used for HD handling: deactivation/decontamination, cleaning, and disinfection. Decontamination (e.g., with peroxide or sodium hypochlorite) renders the HD inert, cleaning (e.g., with a germicidal detergent) removes organic and inorganic material, and disinfection (e.g., with sterile 70% IPA) destroys microorganisms. The order is critical for efficacy and safety.
- A pharmacy technician is assigned to compound a non-sterile topical cream containing tretinoin, a NIOSH Table 3 drug. Which engineering control is most appropriate for this activity?
Answer: A Containment Ventilated Enclosure (CVE) that is externally vented.
Non-sterile HD compounding must be performed in a Containment Primary Engineering Control (C-PEC) that is externally vented. A Containment Ventilated Enclosure (CVE), also known as a powder hood, is designed for this purpose. A standard LAFW provides product protection but not personnel protection and blows air towards the operator, which is unsafe for HDs. A Class I BSC that recirculates air is not appropriate; HD C-PECs must be externally vented.
- A hospital pharmacy uses a Class II Biological Safety Cabinet (BSC) as its C-PEC for sterile HD compounding. Under what circumstance may this C-PEC be turned off?
Answer: It must be operated continuously to maintain negative pressure within the cabinet and C-SEC.
C-PECs used for sterile HD compounding, such as a BSC or CACI, must be operated continuously, 24 hours a day, 7 days a week. This is critical to maintain the negative pressure differential and proper airflow within the cabinet and the surrounding C-SEC, ensuring containment of hazardous drug particles and vapors even when not in active use. Turning it off would compromise the integrity of the containment system.
- A hospital pharmacy needs to transport a compounded syringe of fluorouracil from the central pharmacy to a patient care unit several floors away. According to NIOSH and USP <800> guidelines, what is a key requirement for this transport?
Answer: The syringe must be labeled and placed in a sealed, impact-resistant container.
HDs must be transported in containers that are designed to minimize the risk of breakage or leakage. This means they must be placed in a sealed, labeled, and impact-resistant container (e.g., a plastic bag with a zip closure) that is clearly identified as hazardous. Pneumatic tube systems should generally not be used for liquid HDs due to the risk of breakage. There is no requirement that only a pharmacist can transport them, and freezing is a stability issue, not a transport safety requirement.
- A pharmacy technician receives a tote from a drug wholesaler containing both hazardous and non-hazardous medications. According to USP <800>, what is the proper procedure for unpacking this delivery?
Answer: Unpack the tote in an area that is neutral or normal pressure relative to the surrounding areas.
USP <800> specifies that hazardous drugs (HDs) must be unpacked in an area that is either neutral/normal pressure or negative pressure relative to surrounding areas. Unpacking must NOT be done in sterile compounding areas or in positive pressure areas. Unpacking inside the C-PEC (e.g., a biological safety cabinet) can contaminate the cabinet's work surface.
- What is the primary reason for using a closed-system drug-transfer device (CSTD) as per NIOSH guidelines?
Answer: To prevent release of hazardous drug into the environment during preparation and administration.
This question tests the application of NIOSH guidelines to hazardous drug handling, a key aspect of pharmacy practice on the MPJE. NIOSH provides detailed guidance on safely handling hazardous drugs to protect healthcare workers from exposure. Key measures include the use of PPE, CSTDs, and proper storage techniques. In this context, the question focuses on the role of CSTDs in preventing environmental contamination during hazardous drug handling. For example, using CSTDs minimizes drug aerosolization during compounding and administration. The correct answer, choice A, is supported by the NIOSH guideline that mandates the use of CSTDs to prevent the release of hazardous drugs into the environment, ensuring safety and compliance. Choice B is incorrect because it reflects a misunderstanding of NIOSH guidelines, such as confusing them with USP <797> standards on beyond-use dating; this error often occurs when pharmacists confuse NIOSH with other regulatory bodies. To help students: Encourage familiarity with NIOSH guidelines through scenario-based practice. Emphasize the importance of proper PPE and handling techniques. Teach students to differentiate between NIOSH, OSHA, and FDA guidelines to avoid regulatory confusion.
- After finishing a sterile HD compounding session, a pharmacist is removing their PPE. Where must the outer pair of contaminated gloves and the disposable gown be discarded?
Answer: In a segregated hazardous waste container located inside the C-SEC (buffer room).
Contaminated PPE, such as gowns and outer gloves, must be disposed of before exiting the C-SEC (the buffer room). This requires placing them in an appropriate waste container (e.g., a yellow trace chemo bin) located within the C-SEC itself to prevent tracking contaminants into cleaner areas like the ante-room. Disposing in a regular trash can or red bag is incorrect, and disposal inside the C-PEC is not the designated procedure.
- A pharmacy is designing a new non-sterile compounding area dedicated to hazardous drugs (HDs). Which of the following is a NIOSH and USP <800> requirement for the Containment Secondary Engineering Control (C-SEC) for this purpose?
Answer: It must be externally vented and maintain negative pressure between 0.01 and 0.03 inches of water column.
The C-SEC for HD handling must be externally vented, physically separate from other areas, and have negative pressure between 0.01 and 0.03 inches of water column relative to all adjacent areas. It must also have at least 12 ACPH for a non-sterile C-SEC. Positive pressure is incorrect for HD containment. 30 ACPH is the requirement for sterile compounding buffer areas, not non-sterile HD rooms.
